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Analysis of the OPTN/SRTR database demonstrates
that, in 2002, pediatric recipients accounted for 7% of
all recipients, while pediatric individuals accounted for
14% of deceased organ donors. For children fortunate
enough to receive a transplant, there has been contin-
ued improvement in outcomes following all forms of
transplantation. Current 1-year graft survival is gener-
ally excellent, with survival rates following transplan-
tation in many cases equaling or exceeding those of
all other recipients. In renal transplantation, despite
excellent early graft survival, there is evidence that
long-term graft survival for adolescent recipients is
well below that of other recipients. A causative role
for noncompliance is possible. While the significant
improvements in graft and patient survival are laud-
able, waiting list mortality remains excessive. Pedi-
atric candidates awaiting liver, intestine, and thoracic
transplantation face mortality rates generally greater
than those of their adult counterparts. This finding is
particularly pronounced in patients aged 5 years and
younger. While mortality awaiting transplantation is
an important consideration in refining organ allocation
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strategies, it is important to realize that other issues,
in addition to mortality, are critical for children. Con-
sideration of the impact of end-stage organ disease on
growth and development is often equally important,
both while awaiting and after transplantation.
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Introduction
The data and analysis presented here are meant to provide
a comprehensive overview of issues related specifically to
pediatric transplantation. The data are collected across all
transplant procedures for patients aged 17 years and under
from the OPTN/SRTR database. Unless otherwise noted,
the statistics in this article come from reference tables in
the 2003 OPTN/SRTR Annual Report. Two companion ar-
ticles in this report, ‘Transplant data: sources, collection,
and caveats’ and ‘Analytical approaches for transplant re-
search’, explain the methods of data collection, organiza-
tion, and analysis that serve as the basis for this article
(1,2). Additional detail on the methods of analysis may be
found in the reference tables themselves or in the Techni-
cal Notes of the OPTN/SRTR Annual Report, both available
online at http://www.ustransplant.org.
In considering transplantation as a therapy for pediatric
patients, it is vital to recognize the many and substan-
tial differences between adults and children. These differ-
ences transcend age and size, extending to diverse factors
that include etiology of end-stage organ disease, physiol-
ogy, technical considerations, donor factors, availability of
suitably sized grafts, immunology, pharmacokinetics, and
post-transplant complications. In addition to these factors,
the unique effects of end-stage organ disease and trans-
plantation on development and growth must be carefully
considered.
Over the years, significant progress has been made in pe-
diatric transplantation. Much of this success can be at-
tributed to lessons learned from analyses of registry data.
Along with specific pediatric registries such as the North
American Pediatric Renal Transplant Cooperative Study
(NAPRTCS) and Studies of Pediatric Liver Transplantation
(SPLIT), analyses of data submitted to the OPTN have
shaped practices and policies. One way the SRTR has
contributed to this effort is by providing the first cohesive
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review of pediatric registry data from the OPTN across all
forms of organ transplantation in children (3). Perhaps more
importantly, the SRTR provides ongoing data analyses and
modeling for OPTN committees. Since 2001, the SRTR has
performed 15 analyses for the OPTN pediatric committee.
Examples of such analyses are included in the sections that
follow.
Waiting list overview
At the end of 2002 there were 2307 transplant candidates
younger than 18 years on the waiting lists for various or-
gans, accounting for 3% of all candidates awaiting trans-
plantation. This represents a modest decline from 2382
candidates the previous year and is the first decline in
the last 10 years. This decrease was observed in all pe-
diatric age groups except those 6–10 years old, where the
number of candidates awaiting transplantation increased
minimally. As reviewed in subsequent sections, the de-
crease in the total number of pediatric waiting list candi-
dates reflects a decline in the size of the liver and lung
waiting lists. Overall, pediatric candidates, expressed as
the percentage of all candidates on the waiting list, have
remained stable at around 3% for the last 4 years, although
the continued disproportionate growth of adult candidates
has led to, and will continue to lead to, a gradual decline in
the percentage of the waiting list represented by pediatric
candidates.
Transplant recipients
In 2002, there were 1757 pediatric transplant recipients,
representing 7% of all recipients. This percentage has
been relatively stable over the last 3 years. The more than
twofold higher representation of children among recipients
vs. among candidates may, in part, reflect the preferential
allocation policies in effect that favor pediatric transplanta-
tion. The success of pediatric transplantation is evident by
the prevalence of pediatric recipients who are alive with
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Source:  2003 OPTN/SRTR Annual Report, Table 5.12, 9.12, 10.12, 11.12, 12.12
Figure 1: Prevalence of pediatric transplant recipients living with
a functioning transplant at year-end.
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Figure 2: Adjusted 1-year graft survival for pediatric kidney, liver,
and heart recipients, 1992–2001.
The significant progress made in pediatric transplanta-
tion is apparent when one examines 1-year graft survival
for the three most frequent organ transplants performed
each year over the last decade (Figure 2). When analyzing
changes in outcomes over time, it is particularly important
to correct for any differences in the population under study
that may affect the outcomes. The current report marks
the first attempt to provide adjusted graft and patient sur-
vival for all transplant recipients accounting for a variety of
factors, including age, sex, race, and primary diagnosis. At-
tempts to carry out all adjustments in the pediatric patient
population are limited because of the smaller numbers of
patients; consequently, the adjusted pediatric survival fig-
ures primarily reflect the impact of race and sex. Despite
this limitation, examination of outcomes over the decade
is still instructive. For pediatric recipients, deceased donor
kidney graft survival has increased from 81% in 1992 to
94% for 2001 transplants (Figure 2). Graft survival following
living donor kidney transplantation has also increased (from
90% to 96%). Similarly, deceased donor liver graft survival
has also progressively improved over the decade, with
1-year graft survival of 81% for transplants performed in
2001 compared with 68% a decade previously. Deceased
donor liver graft survival now equals graft survival follow-
ing living donor liver transplantation. Graft survival for heart
transplantation has also increased from 76% to 85% over
the same time period. Further discussion regarding cur-
rent graft and patient survival follows in the organ-specific
sections.
Pediatric donor overview
In 2002, there were 931 pediatric deceased donors, repre-
senting 15% of all deceased donors. Over 56% of these
pediatric donors were aged 11 years and older. The total
number of pediatric deceased donors has declined mod-
estly from a high of 1214 in 1995, although this trend
appears to have stabilized during the last 4 years. The
modest decline in total pediatric donors, combined with
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Figure 3: Deceased donor organs, pediatric vs. adult, 2002.
the significant increase in the total number of adult de-
ceased donors, has caused the relative contribution of
pediatric donors to decline over the decade from a high of
23% in 1993. The relative contributions of pediatric donors
to specific deceased organ donation are summarized in
Figure 3.
As highlighted in the analysis a year ago, pediatric de-
ceased donors continue to be more likely to donate each
specific organ compared with adult deceased donors (3).
This observation remains true. In 2002, pediatric deceased
donors were more likely than adult deceased donors to
be pancreas donors (40% vs. 29%), intestine donors (9%
vs. 0.6%), and heart donors (50% vs. 33%). The percent-
age of pediatric deceased donors compared with adult de-
ceased donors who donated kidneys, livers, and lungs was
similar (92% vs. 91%, 87% vs. 85%, and 16% vs. 15%,
respectively).
Over the last 10 years, the relative percentage of pedi-
atric deceased donors who were kidney, liver, and lung
donors has remained relatively stable. During the same
time, there has been a slight decrease in the percentage
of pediatric donors who were heart donors (from 59% to
50%), while there has been a significant increase in the per-
centage of donors who donated pancreata (23% to 40%)
and intestines (2% to 8%). This trend suggests that there
has been an under-utilization of pancreata and intestines
from deceased pediatric donors in the past. Recent re-
ports demonstrating good long-term results following en
bloc transplantation of kidneys from small pediatric donors
into selected recipients may further increase use of kid-
neys from pediatric donors (4).
In addition to being more likely to donate a particular or-
gan compared with adult deceased donors, pediatric pa-
tients contributed to the total deceased donor organ pool
at a rate higher than the rate pediatric recipients received
such organs (Figure 4). While this observation may reflect
an inability to find a suitable pediatric recipient for a given
cadaveric organ, it demonstrates that the pediatric popula-
Source:2003 OPTN/SRTR Annual Report, Tables 2.1–2.7, 5.4, 6.4, 































Figure 4: Pediatric deceased donors vs. pediatric recipients of
deceased donor organs, 2002.
tion is not receiving a disproportionate share of deceased
donor organs.
There has been a gradually increasing interest in donation
after cardiac death (DCD) over the past several years. A re-
cent SRTR analysis showed that, in 2002, there were 191
DCD donors, of which 32 were younger than 18 years of
age (16.8% of total DCD donors). While pediatric donors
constitute a significant percentage of DCD donors, pedi-
atric recipients do not appear to be receiving organs from
this expanding donor population. In 2002, there were 291
kidney transplants using DCD donor organs, only three of
which were received by pediatric recipients. During the
same time, there were 78 liver transplants performed with
DCD donor livers, only one of which involved a pediatric
recipient. The limited use of DCD donor organs in pediatric
recipients may reflect concern regarding long-term graft
function of such organs. Widespread use of DCD donor
grafts in pediatric recipients is unlikely until further data
regarding this issue are available.
Kidney Transplantation
The transplant community has long recognized that indica-
tions, endpoints, procedures, complications, pharmacoki-
netics, and outcomes of kidney transplantation are dif-
ferent for children than they are for adults. In response
to those differences, dedicated pediatric registries, such
as the NAPRTCS and multicenter studies such as Coop-
erative Clinical Trials in Pediatric Transplantation (CCTPT)
have been developed to address the special requirements
of children (5,6). At the same time, more comprehensive
databases, such as the SRTR, are essential for defining
the comparative outcomes of children and adults and for
defining opportunities for improving the outcomes of both
groups (3).
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In the past, young kidney recipients have been considered
high risk, with diminished graft survival compared with
older children and adults (6,7). In many reports, the worst
survivals were seen in the youngest patients. However,
many improvements by pediatric kidney transplant teams,
including changes in surgical technique, donor selection,
immunosuppression practices, and development of dedi-
cated pediatric kidney transplant research programs have
led to marked improvements in patient and kidney graft sur-
vival for infants and young children (5,8–10). As a result,
recent analyses, including last year’s SRTR report, have
identified that infants and young children currently have
the best long-term survivals of all age groups (3). In fact,
one report has identified the subgroup of young recipients
of adult-sized kidneys who have immediate graft function
as having the longest projected graft half-lives of all re-
cipient groups, exceeding even those of adult recipients of
2-haplotype matched living donor transplants (11). Unfortu-
nately, adolescent kidney transplant recipients have worse
outcomes than infants and younger children, and research
efforts should be redirected to that age group to identify
the causes of inferior results and to correct any deficien-
cies, as has been done for younger children over the past
decade.
Waiting list
The incidence of end-stage renal disease in children has in-
creased only slightly during the past decade, and this has
been reflected in the waiting list for diseased donor kidney
transplants. In 1993, there were 591 children aged under
18 years listed for kidney transplants; by 2002 there were
708, an increase of only 20%. In contrast, the number of
listed adults more than doubled, from 22 905 to 50 147. It is
of note that the increases were not seen uniformly through-
out the adult age groups. While the number of young adults
aged 18–34 years increased by just 27% during that time
frame, those aged 50–64 years increased by more than
threefold, and those over 65 years by over fivefold. The
waiting list is indeed ageing. As a result, the percentage of
children on the kidney waiting list decreased from 2.5% to
just 1.4% during the past decade. The relative distribution
by pediatric age groups has remained stable over the last
10 years. Of the pediatric patients on the waiting list at
the end of 2002, 70% were in the 11–17 years age range.
Children under 1 years are rarely listed for cadaveric renal
transplant, and only one such patient was on the waiting
list at the end of 2002.
Another perspective of relative incidence can be gained
from analyzing the number of new kidney waiting list reg-
istrations in different time periods. In 1993, 420 children un-
der 18 years were added to the kidney waiting list, whereas
in 2002, 546 were added, a 30% increase. In the same
time period, the numbers of adults were 14 598 and 21
373, respectively. Thus, children represented about 3% of
new registrants throughout the decade. Within the pedi-
atric population, the greatest increase in new registrants
over the last 10 years has been in the 11–17 years age
range.
Annual death rates for pediatric registrants awaiting renal
transplantation are low and have remained relatively con-
stant over the last 10 years. Last year 23 children died
while awaiting kidney transplantation. The death rate for
children aged 1–5 years was the highest of all pediatric pa-
tients awaiting renal transplantation (61 per 1000 patient
years at risk), while the lowest rate was observed in the
6–10 years age range (17 per 1000 patient years at risk).
The latter age group had the lowest annual death rate of
any age patient awaiting transplantation, while the death
rate observed in younger children approached that seen in
adults aged 50–64 years. Children aged 11–17 years had
an annual death rate equal to adults in the 18–34 years age
group.
The OPTN has always provided preference for chil-
dren awaiting deceased donor renal transplants. Initially,
children were preferentially allocated kidneys from young
deceased donors under 10 years. Unfortunately, these
donors turned out to be high risk, probably because of
technical complications; young recipients seemed partic-
ularly susceptible to graft failure, often related to graft
thrombosis (12,13). Subsequently, the allocation system
was changed, first by additional points and next to the
present system of placing the pediatric patients at the top
of the waiting list after waiting times between 6 and 18
months. This newer system has contributed to improve-
ment in graft outcome for children while maintaining rel-
atively short waiting times. The median waiting times for
those aged 6–10 years at listing, for example, was 310 days
in 1993 and 379 days in 2002; for those 11–17 years old
it decreased from 450 days in 1993 to 415 days in 2001.
The waiting times for other pediatric age groups remained
comparably low while the median waiting times of adults
have increased to over 1000 days.
Pediatric patients are rarely listed for pancreas transplant
or, even less frequently, for kidney-pancreas transplant. As
a consequence of the small number of pediatric patients
who are candidates for these transplants, meaningful anal-
ysis of wait time or mortality awaiting transplant is not
feasible.
Transplantation and survival
There were 769 pediatric kidney transplant recipients in
2002 compared with 661 in 1993. Last year, deceased
donor renal transplants accounted for 327 (43%), while 442
were living donors (57%). Overall, a greater percentage
of pediatric patients received a living donor kidney com-
pared with adults, because only 41% of adult recipients
received a living donor kidney transplant. The proportion of
living donor renal transplants was inversely related to re-
cipient age (Figure 5). With respect to deceased donor kid-
neys, there is essentially no use of extended criteria donor
(ECD) kidneys in pediatric recipients. In 1998, 17 children
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Figure 5: Pediatric kidney transplants, by recipient age, 2002.
received ECD deceased donor kidneys, but the number fell
to just one in 2002.
Graft survival rates of pediatric kidney recipients have im-
proved substantially during the past decade and now rank
among the best of all transplants (10). This outcome may
seem surprising in view of the previous perception of chil-
dren having poor outcomes of kidney transplantation. Pedi-
atric recipients younger than 10 years who received living
donor kidney transplants have 5-year adjusted graft survival
rates that were better than all age groups of adults (88%
for those under age 1 year, 84% for those 1–5 years, and
85% for those 6–10 years) (Figure 6). The results of de-
ceased donor kidney transplants are similar, with the 1–5
year old recipients having a 72% 5-year adjusted graft sur-
vival rate and those 6–10 years having the best adjusted
graft survival rate of all age groups at 77% (Figure 7). In
contrast, the best outcome seen in adults is 69% 5-year
graft survival in 35–49 year olds. These outcomes are in
94.3 96 94.9 94.8 94.9 93.5 91.6
84.3 84.9
72.2



























Figure 6: Adjusted 1- and 5-year graft survival of living donor kid-
ney transplants by recipient age, 2002.
Source: 2003 OPTN/SRTR Annual Report,Table 5.8a. 
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Figure 7: Adjusted 1- and 5-year graft survival of deceased donor
kidney transplants by recipient age, 2002.
concert with recent reports showing that the longest half-
lives of all recipients are in the youngest recipients, espe-
cially the pediatric recipients of adult-sized grafts who have
immediate graft function (8,11). Unfortunately, these excel-
lent results in young children are not seen in adolescent re-
cipients. For 11–17 year old recipients, the 5-year adjusted
graft survival rate of living donor kidneys is only 72%; for
deceased donor kidneys it is 60%. These results are worse
than all other age groups except those older than 65 years.
These recipients generally have excellent short-term (3-
month and 1-year) graft survival rates, but graft losses be-
tween 3 and 5 years are striking. The reasons for this poor
outcome are not known, but there is speculation about the
role of compliance with immunosuppressive medications
(14). Thus far, no studies have been done to determine
all the factors leading to the lower graft survival in this
adolescent cohort. Of course, other causes are also possi-
ble (15), including an unexplained high frequency of graft
thrombosis (16) and the high incidence of recurrence of
focal segmental glomerulosclerosis (FSGS), which is the
most common acquired cause of ESRD in this age group
(17). Until the causes of this diminished graft survival are
known, special attention should be paid to this new high-
risk age group.
Recent studies suggest that in the pediatric age group, the
difference between short-term graft survival for deceased
donor kidneys vs. living donor kidneys appears to be de-
creasing (18). The current data support that finding; 1-year
unadjusted graft survival in children older than 1 year of
age ranged from 93% to 95% for deceased donor kidney
transplants and 94% to 96% for living donor kidney trans-
plants. This probably reflects advances in overall manage-
ment, as well as improved selection of deceased kidney
donors. The impact of better donor selection is suggested
by the percentage of pediatric deceased donor recipients
who receive dialysis in the first week after transplantation
(Figure 8). The percentage of pediatric recipients requiring
58 American Journal of Transplantation 2004; 4 (Suppl. 9): 54–71
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Figure 8: Deceased donor kidney transplant recipients receiving
dialysis in first week following transplant.
Source: 2003 OPTN/SRTR Annual Report, Table 5.10a, 5.10b. 



























Figure 9: Adjusted five-year patient survival of living and de-
ceased donor kidney transplants by recipient age, 2002.
dialysis is lower than adult recipients and has declined over
the decade.
As expected, the death rates of pediatric kidney transplant
recipients were generally lower than those of adults and
5-year patient survival rates were better (Figure 9). The ad-
justed 5-year patient survival rate of adolescent living donor
kidney transplants was only 96%, and the reasons for this
apparent recent decrease in survival deserve further study.
There is some concern that infection rates following renal
transplantation may be increasing and may pose a risk for
patient survival (19,20). Also, the youngest recipients ap-
pear to have a slightly higher death rate than other children
and young adults in some years. There are so few patients
and deaths in this age group, however, that the significance
of the finding is not clear, and, even if true, it may be diffi-
cult to define a cause of excess mortality.
The use of children as kidney donors has not been well
studied. The number of pediatric deceased donors has de-
clined slightly over the decade. In 1993, there were 1026
deceased kidney donors aged under 18 years; in 2002 there
were 853. Those numbers represented 22% and 15% of
the total number of deceased donors in those years, re-
spectively. As highlighted in the donor overview (Figure 4),
the percentage of pediatric deceased donors currently is
substantially greater than the percentage of pediatric can-
didates on the waiting list (1.5%) or deceased donor kidney
recipients (4.5%). Kidneys from donors aged 11–17 years
generally had the best graft survival rates, with a 5-year
graft survival of 73%. Grafts from younger donors, how-
ever, were less successful. The 5-year graft survival rates
from deceased donors aged 1–5 years was 66%, which is
better than in previous years and equivalent to those from
donors aged 35–49 years (65%) and superior to those of
donors aged over 65 years (44%). Thus, kidneys from those
very young donors are surviving much better than in the
past, and the use of those donors for selected recipients
should be encouraged (4,21). The use of children for living
kidney donation remains highly controversial, and in gen-
eral, most transplant programs will not use a donor younger
than 18 years of age as a living kidney donor except in very
limited circumstances, such as identical twins or an eman-
cipated minor for his or her own child (22). There were 36
living adolescent kidney donors between 1993 and 2002.
A recent analysis of OPTN data suggested that many of
these donors were used for adult recipients (23).
In summary, the past decade has seen substantial improve-
ment in graft survival for pediatric renal transplant recipi-
ents. Children under 10 years of age now have the best
long-term graft and patient survival rates of all transplant
recipients. This success, however, is not shared by adoles-
cent recipients, and further study of the factors responsible
for this finding is needed if improvement is to occur. Con-
tinued attention to recipient risk factors associated with
graft loss (24), improvements in donor selection, operative
techniques, immunosuppressive protocols, and long-term
follow up are all possible approaches for improving the out-
comes in pediatric recipients. Children are generally trans-
planted early in the course of ESRD care, because the ma-
jority of these patients receive grafts from living donors.
Those on the list for deceased donor organs wait shorter
periods of time than adults, because the allocation proto-
cols provide them with preference.
Liver Transplantation
As mentioned in the introduction, it is critical to recognize
that pediatric liver transplant recipients are a distinct pop-
ulation, not only with respect to age, but also with respect
to primary diagnosis, type of graft, donor population, and
post-transplant complications. Consequently, the effect of
changes in organ allocation and care processes cannot be
generalized from adults to children. As part of its ongoing
data analyses, the SRTR regularly performs in-depth exam-
ination related to pediatric patients, examples of which are
included in this section. Additionally, the SRTR is commit-
ted to ongoing collaboration with other efforts specifically
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focusing on the study of liver disease and liver transplan-
tation in pediatric patients, including SPLIT and the recent
NIH initiative, BARC (Biliary Atresia Research Consortium).
Waiting list
At the end of 2002, 955 candidates under 18 years of age
were awaiting liver transplantation, compared with 427 pe-
diatric candidates in 1993. While the number of children
on the waiting list has increased more than twofold since
1993, the total number of adults has increased sixfold, and
the number of those older than 50 years has increased
eightfold. As a result, pediatric candidates now account for
6% of the waiting list compared with 15% in 1993. Nev-
ertheless, since 1998, the proportion of children on the
waiting list has been stable, ranging between 5.6% and
6.8% of registrants.
In 2002, the first decline in a decade was seen in the num-
ber of new registrants placed on the liver transplant wait-
ing list. There were 804 new pediatric registrations in 2002
compared with 984 in 2001. A similar decline was noted for
adult registrants; 8141 adults were listed in 2002 compared
with 9361 in 2001. Within the pediatric age groups, this de-
cline in new registrations was noted across all age groups
but was greatest in the 11–17 year old age range, where
there was a 29% decrease in new registrations compared
with 2001. The significance of this decline is undetermined,
but it may represent changes in practice after the introduc-
tion of allocation based on the Model for End-stage Liver
Disease (MELD) and its counterpart for children, the Pe-
diatric End-stage Liver Disease (PELD) model. Now that
waiting time no longer plays a meaningful role in the allo-
cation of deceased donor livers, patients do not need to
become listed simply to accrue waiting time. It is unlikely
that this decline reflects a decrease in the incidence of end-
stage liver disease or the introduction of other treatment
alternatives.
Despite the increased waiting list and a limited pool of or-
gans, the median time from listing to transplantation for
pediatric candidates has not increased from 1993 to 2002.
In contrast, the median time to transplantation for candi-
dates older than 18 years has increased fivefold over the
same time period. The observations indicate that the in-
creased demand for adult liver transplantation has not ad-
versely affected the availability of deceased organ donors
for pediatric candidates. Within the pediatric population,
the median time to transplant for pediatric registrants listed
in 2002 is higher in children younger than 1 year and those
aged 1–5 years (209 and 203 days, respectively), compared
with children aged 6–10 and 11–17 years (170 and 147
days, respectively).
On February 27, 2002, the MELD and PELD scoring sys-
tems were implemented for allocation of deceased donor
livers. The median time to transplant was 243 days for reg-
istrants listed with a PELD score of 11 or less, 138 days
for registrants with a PELD score of 11–20, 125 days for
registrants with a PELD score of 21–30, and 15 days for
registrants with a PELD score greater than 30. The longer
waiting times for adult recipients mean that the median
time to transplant as a function of MELD score is available
only for candidates with scores greater than 20. For these
two groups (MELD scores of 21–30 and greater than 30),
the median time to transplant was 128 days and 29 days,
respectively, similar to the time to transplant for children
with comparable PELD scores.
At present, a robust analysis of the impact of the PELD
system on pediatric liver transplantation is not possible,
given the small numbers of pediatric candidates. With this
caveat, analysis performed by the SRTR has suggested
some trends worthy of future study, including the obser-
vation that patients with an increasing PELD score over
time were found to have a higher mortality than children
with a stable PELD score. In an accompanying article in
this report, ‘Improving liver allocation: MELD and PELD’,
by Freeman et al., an increasing PELD score over the pre-
vious 30 days (PELD) was found to significantly increase
the relative risk of death on the waiting list (RR = 1.10,
p < 0.0001) (25).
Pretransplant mortality is a critical endpoint in examining
the outcome of the waiting list process. The total num-
ber of deaths for all candidates on the liver waiting list has
increased from 579 in 1993 to 1818 in 2002. During the
same period, the number of pediatric candidates who died
awaiting liver transplantation remained stable, but the pro-
portion of deaths accounted for by pediatric candidates on
the waiting list decreased. Candidates under 18 years of
age accounted for only 5% of deaths on the waiting list in
2002 compared with 15% in 1993. This decline parallels the
decreasing proportion of pediatric patients awaiting trans-
plantation compared with adult recipients, although there
has been a decline in the annual death rate for both chil-
dren and adults over the decade. While the total number
of deaths has increased, the annual death rate per 1000
patient years decreased from 225 in 1993 to 106 in 2002
for all age groups. The trend has been gradual and con-
sistent for all candidates older than 1 year. For children
younger than 1 year, however, the death rate in 2002 was
766 per 1000 patient years, which is sixfold higher than the
overall death rate for all candidates and exceeds the rate
observed among patients listed as OPTN/UNOS Status I.
Furthermore, in marked contrast to the decline observed
in all other age groups, the death rate for infants, on aver-
age, has not changed since 1993. The reason for the high
death rate in these infants is probably multifactorial. Rea-
sons may include an allocation system that does not fully
reflect the relative risk of mortality for these small children,
limitations in the medical management of listed patients,
difficulty finding suitable grafts, and other factors related to
the ability to offer transplantation as a therapeutic option to
this particularly complex and technically challenging subset
of children. Additionally, patients awaiting a liver-intestine
transplant are also considered in the analysis of liver
60 American Journal of Transplantation 2004; 4 (Suppl. 9): 54–71
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waiting list mortality. While the number of liver-intestine
candidates is small, they are disproportionately repre-
sented among children younger than 5 years of age.
Deceased donor liver transplantation
In 2002, 482 children aged under 18 years received de-
ceased donor liver transplants, a figure that has remained
relatively stable over the last decade. However, when we
examine the proportion of deceased donor liver transplants
allocated to children, the results differ. Specifically, this pro-
portion has progressively declined in increments over the
course of the decade. In 1993 and 1994, approximately
14% of deceased donor organs were allocated to pedi-
atric recipients; from 1995 through 1998, this figure was
12%; and in 1999, it declined to 10%. The proportion has
remained stable since that time.
Living donor liver transplantation
In an effort to address the shortage of deceased donor
livers, living donor liver transplantation was introduced in
1989. Until 1999, the majority of living donor liver transplant
recipients were pediatric patients. With the introduction
of adult-to-adult living donor transplants, the percentage
of total living donors in children has decreased. The total
number of adults and children who received living donor
liver transplants has generally increased over the decade,
although there was a modest decline in total living donor
liver transplants performed in 2002.
In 2002, 72 children received living donor liver transplants,
accounting for 20% of all living donor liver transplant re-
cipients. The proportion of pediatric recipients in each age
group who received living donor liver transplants compared
with deceased donor liver transplants was inversely propor-
tional to age (Figure 10). Children aged 5 years and younger
accounted for 86% of pediatric living donor liver recipients.
There was a modest decrease in the number of living donor
transplants performed in children in this younger age range
in 2002 compared with the previous year (62 in 2002; 79
in 2001). The introduction of right lobe living donor liver
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Figure 10: Pediatric living donor liver transplants, by recipient age,
2002.
transplant has not significantly affected the overall num-
ber of living donor liver transplants performed in children
in the 11–17 year age range. It is likely that these recipients
are too small for an adult right lobe graft, thus limiting the
applicability of this technique to a small number of older
pediatric patients.
Patient and graft survival
Patient survival in the first year after transplant, expressed
as annual death rates per 1000 patient years, was simi-
lar for all age groups except children younger than 1 year
(Figure 11). Prior to 2001, the death rate for this group was
at least twofold higher than that of any other age group.
For such infant recipients transplanted in 2001 and 2002,
there was a marked decline in the death rate, although the
rate currently remains higher than that for all age groups.
For children aged 1–5 years and those aged 11–17 years,
the time trend indicates a decreasing death rate.
Deceased donor graft survival was similar for all ages, with
the exception of those transplant recipients younger than
1 year or older than 65 years, both of whom had lower
survival rates at 3 months, 1 year, 3 years, and 5 years after
liver transplantation than other intermediate age groups, al-
though many of the differences are not statistically signifi-
cant. Across all age groups, current 1-year patient survival
after deceased donor liver transplant is highest among re-
cipients 6–10 and 11–17 years of age (94% and 93%, re-
spectively), whereas 1-year adult patient survival ranges
from 86% to 88% for recipients under 65 years of age
(Figure 12). When examined as a function of donor type,
graft and patient survival for children younger than 1 year
was greater if they received an allograft from a living donor
compared with a deceased donor, a trend not detected for
any other age group (Figure 13). This trend reached sta-
tistical significance for the cohort at the 5-year time point.
This finding is consistent with preliminary data presented
by two groups at the American Transplant Congress; the
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Source: 2003 OPTN/SRTR Annual Report,Table 9.7
Figure 11: Death rate in the first year following liver transplant,
1993–2002.
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Source: 2003 OPTN/SRTR Annual Report, Table 9.11a and 9.11b
Figure 12: One-year unadjusted patient survival of deceased and
living donor liver transplants by recipient age, 2002.
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Figure 13: Unadjusted liver graft and patient survival for children
less than 1 year of age.
than 2 years if they received an allograft from a living donor
compared with a deceased donor (26,27).
The effect of primary diagnosis on long-term outcome fol-
lowing liver transplantation was recently examined as part
of a data request by the OPTN Pediatric Transplant Com-
mittee. Pediatric recipients who received a primary liver
transplant between 1995 and 1999 were followed until
death or 5-year follow-up was reached. A total of 2134
recipients were identified. The most common primary di-
agnoses were biliary atresia (46%), acute hepatic necrosis
(14%), metabolic diseases (12%), noncholestatic cirrhosis
(10%), and cholestatic liver disease (4%). Recipients with
other diagnoses or missing diagnosis accounted for 10%.
As demonstrated in Figure 14, patient survival for biliary
atresia, metabolic diseases, noncholestatic cirrhosis, and
cholestatic liver disease was similar, with 1-year survival
of 87–88% and 5-year survival of 80–84%. As expected,
recipients with acute hepatic necrosis had lower survival;
78% at 1 year and 71% at 5 years. Children transplanted
Figure 14: Kaplan-Meier survival curves by primary diagnosis, pe-
diatric recipients of livers.
with hepatocellular carcinoma (n = 8), and other malignant
neoplasms (n = 26) had 5-year survival of 63% and 65%,
respectively. Although the numbers of such patients are
small, the results after transplantation in this patient pop-
ulation are discouraging. Children transplanted for hepato-
blastoma (n = 42) appear to fare better than those trans-
planted for other malignancies, with 86% survival at 1 year
and 79% survival at 5 years, but the confidence intervals
are wide because of the small sample sizes.
In summary, despite increased demand for liver trans-
plantation and increased waiting time to transplantation,
pretransplant mortality has decreased and patient and
deceased donor allograft survival have improved. When
compared with other age groups, however, children aged
under 1 year continue to have increased pretransplant mor-
tality and lower patient and allograft survival. Patients in
this group tend to show improved survival when receiv-
ing an allograft from a living donor compared with those
who receive an allograft from a deceased donor. While
this advantage is at times small, it suggests that these pa-
tients should at least be considered for living donor trans-
plant if the severity of their liver disease warrants this
intervention.
Intestinal Transplantation
Intestinal transplantation has become a clinical reality over
the past decade, as witnessed by reports from the Uni-
versity of Pittsburgh (28), University of Nebraska (29), Uni-
versity of Miami (30), Mt. Sinai Medical Center (31), and
the University of California, Los Angeles (32). Infection
and rejection continue to be barriers to more widespread
application of the procedure. Finding organs of suitable
size and quality for this unique group of transplant re-
cipients is another major challenge facing the field. This
fact was highlighted by a recent report demonstrating
the higher waiting list mortality among candidates for
intestinal grafts (33). Overall, there has been a marked
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improvement since 1997 in outcomes following intestinal
transplantation.
Waiting list
There have been no major changes in the listing status
of patients awaiting intestinal transplantation, because all
are listed as urgent, nonurgent, or inactive. For patients
awaiting intestines in combination with the liver, there have
been major changes in the allocation of liver grafts after the
introduction of MELD/PELD. The MELD/PELD allocation
system was tested in a cohort of end-stage liver disease
patients that excluded liver-intestine candidates, therefore
it does not adequately predict death rates for patients
with total parenteral nutrition (TPN)-associated/intestinal
failure type of liver disease (33). A recent SRTR analy-
sis of waiting list mortality for pediatric liver candidates
and liver intestine candidates revealed that while PELD
was predictive of mortality in both patient populations,
the mortality risk for the same PELD score is higher for
liver-intestine candidates compared with candidates await-
ing liver transplant alone. This finding has led to changes
in OPTN/UNOS organ allocation policy, wherein patients
awaiting liver-intestine transplant automatically receive an
increase in their MELD/PELD score equivalent to a 10%
risk of 3-month mortality. Additionally, livers may be of-
fered to multi-organ recipients after Status 1 liver candi-
dates but before other isolated liver transplant candidates
(OPTN/UNOS Policies 3.6.4.7, 3.9.3, and 3.11.4) (34).
Over the past decade, the demand for intestine transplants
has increased significantly. There were a total of 187 can-
didates on the waiting list at the end of 2002, of whom
137 were younger than 18 years of age. While this rep-
resents a substantial increase from 1993, there was little
change from the previous year. Nearly 50% of all candi-
dates awaiting intestinal transplantation were younger than
5 years, and the majority were non-Hispanic/non-Latino
whites. These ratios have remained relatively constant.
The number of new registrants in each age range has re-
mained stable over the past 3 years. Of the total 129 new
pediatric registrants in 2002, 80 were younger than 1 year
and 31 were in the 1–5 year age range. The median time
to transplant reflects the difficulty facing these candidates
awaiting intestinal transplantation. The overall median time
to transplant for all candidates in 2002 was 310 days, a fig-
ure that has not changed substantially since 1998. Median
time to transplant is lowest for candidates in the 50–64
year age range and between 200 and 300 days for all other
age groups. A median time to transplant cannot be calcu-
lated yet for infant candidates (<1 year old), reflecting the
long waiting time to transplant in this age group.
The substantial waiting times for intestinal transplantation
translate into significant waiting list mortality. In 2002, the
annual death rate per 1000 patient years was 298 for the
total candidate group. These rates were even more stag-
gering in the groups aged under 1 year and 1–5 years (631
and 371, respectively). This waiting list mortality is par-
ticularly troublesome when one considers the number of
deceased donors in 2002. In that year, there were 6182
deceased donors, while there were only 187 candidates
awaiting intestinal transplantation. Taking potential techni-
cal considerations related to size into account, even for
small children (age 5 years and under), there were 270
deceased donors in this age range and 96 potential recipi-
ents in the same age range. This discrepancy between the
number of deceased donors, candidate waiting times, and
candidate waiting list mortality point to the imperative of
addressing long waiting times and the difficulty of match-
ing donor intestines to potential recipients. Other current
literature also support the data showing that the waiting
list death rates in this group of patients are substantially
higher than those reported for any other group of solid or-
gan transplant candidates. Pretransplant mortality rates as
high as 50% have been reported in the literature from in-
dividual transplant centers (35,36). The advanced medical
condition of these patients at the time of evaluation and
the limited availability of organs of suitable size and qual-
ity no doubt contribute to the high mortality rates among
these patients.
Transplantation and survival
In 2002, there were 67 intestinal transplants in pediatric
recipients, accounting for 63% of all intestinal transplants
performed. Within the pediatric population, 66% of these
recipients were aged 5 years or younger. The character-
istics of these intestinal transplant recipients are similar
to those of the intestinal transplant candidates described
above. The incidence of intestinal transplants per one mil-
lion population is very low, and this figure has not changed
much over the past several years. As compared with kid-
ney transplants (incidence 51.22 per one million population)
and liver transplants (incidence 18.47 per one million pop-
ulation), the incidence of intestinal transplants in 2002 was
0.37 per one million population. The age groups with the
highest incidence of intestinal transplants are infants (un-
der 1 year of age) and 1–5 year olds (incidence 5.27 per one
million population). This low incidence reflects the smaller
number of patients currently considered candidates for in-
testinal transplantation. It is not possible to know if the
low incidence also reflects limited access for patients to
the few centers that actually perform these transplants on
a regular basis.
Outcomes after intestinal transplantation have generally
improved over the last 10 years. In 2002, the overall recip-
ient death rate in the first year after intestinal transplant
per 1000 patient years at risk was 318. For comparison,
the corresponding figure for recipients of liver transplants
was 145. In the intestinal transplant data, the death rate
has shown an overall decrease since 1993, but it remains
highest in the 1–5 year and 6–10 year age groups (384
and 513, respectively). The death rate is also affected,
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Figure 15: Unadjusted intestine patient survival for children by
recipient age.
notably by donor age, such that recipients of intestines
from donors aged 6–10 years had a substantially higher
death rate. Graft survival rates after intestinal transplant
for all age groups at 3 months, 1 year, 3 years, and 5 years
were 86%, 71%, 43%, and 33%, respectively. It should
be noted that graft survival rates were much higher for
recipients of liver transplants than for intestinal transplant
recipients.
Overall patient survival rates in 2002 following intestinal
transplantation at 3 months, 1 year, 3 years, and 5 years
were 81%, 70%, 57%, and 44%, respectively. As illus-
trated in Figure 15, 1-year patient survival rates in the 6–10
and 11–17 year ranges (89% and 100%, respectively) ap-
pear higher than those observed in younger children (44%
for patients aged less than 1 year and 64% for recipients
aged 1–5 years). The corresponding survival rates for re-
cipients of liver transplants were much higher than those
for intestinal transplant recipients.
To put these outcome data into perspective, one needs
to examine the existing literature on intestinal transplan-
tation. The International Intestinal Transplant Registry (37)
is the only data source with comparable patient numbers.
The most recent publication reports 273 transplants in 260
patients. A combined liver-intestinal graft was used in 48%
of recipients, while an isolated intestinal graft was used in
41%. The most common pediatric indications for transplant
were volvulus, gastroschisis, and necrotizing enterocoli-
tis; the most common indications in adults were ischemia,
Crohn’s disease, trauma, and desmoid tumors. There was
a better outcome in patients transplanted since 1995 and in
patients transplanted in centers that had performed 10 or
more total transplants. Although the survival is only calcu-
lated to 2 years post-transplant, the figures are comparable
to those cited in this report. These published findings mir-
ror the registry’s most recent in-depth analysis of 437 in-
testine transplants performed in 405 pediatric recipients as
of May 2001 (38). Overall patient and graft survival appear
to be improving. Pediatric recipients now account for 63%
of the total transplants in the registry. The major cause of
death after transplant remains sepsis. Other published se-
ries overwhelmingly indicate that the major cause of graft
loss after intestinal transplantation is immunological due to
acute or chronic rejection (28–32).
Publications from large, single-center studies also indicate
overall improving outcomes (28–32). Five-year patient and
graft survival rates from 55% to 90% and from 50% to
60%, respectively, have been reported recently. The rea-
sons for these improvements are multifactorial. Earlier re-
ferral for transplantation facilitates obtaining suitable donor
organs prior to the deterioration of the recipient’s clinical
condition. The experience of the transplant center may
also play a role, as outlined above. Improvements in im-
munotherapy with the introduction of interleukin-2 recep-
tor antagonists (39,40), rapamycin (31), thymoglobulin (41),
and alemtuzumab (42) have led to the reduction in the in-
cidence and severity of graft loss and patient morbidity.
Furthermore, improvements in antimicrobial prophylaxis
and treatment of organisms such as cytomegalovirus and
Epstein-Barr virus have reduced the effect of these viruses
after intestinal transplantation (43).
In summary, the data demonstrate a small but growing pop-
ulation of candidates and recipients waiting for and under-
going intestinal transplantation. The vast majority of these
patients are currently managed in four or five transplant
centers in the USA. The data demonstrate that mortality
on the intestinal transplant candidate waiting list is unac-
ceptably high. These findings have led to recent changes
in the allocation system. It remains to be seen if these
changes will affect waiting list outcomes. The data also
show a very small number of individuals being listed for
intestinal transplantation. Whether this indicates a small
incidence of the diseases that lead to intestinal failure or
a low rate of patients with these diseases being referred
and listed for intestinal transplantation remains specula-
tive. Outcomes after intestinal transplantation, particularly
in the short term, are steadily improving.
Heart Transplantation
Waiting list
While the number of pediatric patients awaiting heart trans-
plantation has been relatively steady over the last 5 years,
the 262 patients listed at the end of 2002 represent a 10%
increase compared with the end of 2001. Pediatric patients
continue to account for 5–7% of all of those awaiting heart
transplants. Of all pediatric patients on the waiting list at
the end of 2002, 40% were in the 1–5 year age range. Fol-
lowing the trend of the last 3 years, the number of new
pediatric heart transplant registrants aged less than 1 year
continued to increase and to predominate over the other
pediatric age groups in 2002. An increase in the number of
new pediatric heart registrants in the 1–5 year age range
seen in 2001 was sustained in 2002, and the number in
64 American Journal of Transplantation 2004; 4 (Suppl. 9): 54–71
Pediatric transplantation
the 6–10 year group rose to levels approximating those of
the last half decade after an unexplained decline last year.
High-risk congenital cardiac anomalies unsuitable for sur-
gical intervention or those for which surgical repair has not
provided adequate palliation are the most frequent indica-
tions resulting in transplant in candidates under 1 year of
age. The diagnosis of cardiomyopathy ultimately accounts
for the majority of transplants performed in children (1–10
years of age), as well as adolescents (11–17 years of age),
although congenital heart disease does account for 25%
of transplants in the latter group (44).
Pediatric groups older than 1 year of age have a median
waiting time to transplant of less than 3 months; those
less than 1 year have insufficient data to make this deter-
mination because of longer waiting times and extremely
high waiting list mortality in the infant population. The time
to transplant for children older than 1 year remains sub-
stantially shorter than for adult registrants. Also of note is
median time to transplant for candidates in the 1–5 year
age range, which was 50% shorter in 2002 compared with
2000. Despite this shorter waiting time, the rate of death
on the waiting list in pediatric registrants remains a major
problem. The death rate for all pediatric heart waiting list
patients is well above the rate for all adult age groups. In-
fants (aged less than 1 year) have a death rate more than
six times that seen in other pediatric age groups and more
than 10 times the overall cardiac waiting list mortality rate.
This reflects both the severity and the unstable nature of
the pathophysiology associated with these complex con-
genital heart lesions. These data emphasize the critical
issue of a shortage of donor organs as well as the inad-
equacy of extracorporeal support systems for children.
Transplantation and survival
Over the last 10 years, children have accounted for approx-
imately 13% of all heart transplant recipients. Similarly,
over this same period, the percentage of all heart recipi-
ents who carried the primary diagnosis of congenital heart
disease has remained stable at just over 8%. The number
of transplants performed has remained relatively stable in
each pediatric age group over the last 5 years, with 60–80
transplants annually in infants, 55–82 transplants in recipi-
ents aged 1–5 years, 28–46 transplants in the 5–10 year age
range, and 88–99 transplants in adolescents. After patients
in the 50–64 year age range, infants consistently have the
second highest incidence of heart transplant, with a range
of 16–28 per one million population over the last 10 years.
Excluding individuals in the 50–64 year age group, this in-
cidence is approximately three to eight times that seen in
all other age groups.
Over the last 10 years, donor or recipient age under 1 year
has generally been associated with a higher annual death
rate per 1000 patient years for recipients in the first year
after heart transplantation. There are several postulated
reasons for higher mortality in this age group. First, the
complex congenital heart lesions that are not amenable
to surgical palliation are frequently associated with pul-
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Figure 16: Unadjusted heart patient survival for children by recip-
ient age.
monary over-circulation and can result in both decreased
end organ perfusion as well as elevated pulmonary vascu-
lar resistance as the patient awaits a suitable donor organ.
Furthermore, from the aspect of the donor organ, there
may be a poorly understood susceptibility of the immature
myocardium to preservation or reperfusion injury. Despite
this higher mortality in the first year following transplant
in infant recipients, at 5 years following transplantation,
the survival is similar to that seen in all other age groups
(Figure 16). This equilibration in survival that occurs by
5 years following the transplant may be related to emerging
evidence that rejection is reduced in thoracic organ recipi-
ents when transplanted in the first year of life (45). Trans-
plantation performed in infancy may confer some type of
immunologic tolerance that, as of yet, is not well under-
stood. Notably, 5-year patient survival for recipients in the
6–10 year age range is higher than that seen in any other
age group, including the adult population. The reasons for
this are unclear from available data and warrant further
investigation.
In summary, the issue of inadequate donor organ supply
remains an obvious obstacle in pediatric heart transplan-
tation. The number of candidates on the waiting list, the
number of transplants performed, and outcomes follow-
ing transplantation have all remained relatively stable. In-
novative technology for supporting ill candidates to the
time of transplant, aggressive approaches for expanding
the donor pool—including the continued development of
novel strategies such as nonheartbeating donors and ABO
incompatible donors and the development of novel forms
of immunosuppression—are essential for future improve-
ment in the field.
Lung Transplantation
Waiting list
Similar to the heart transplant population, pediatric pa-
tients represented only 5–6% of all patients on the lung
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Figure 17: New pediatric registrations on the lung transplantation
waiting list, 1993–2002.
transplant waiting list over the last 10 years. While the to-
tal number of pediatric patients is small, some trends can
be identified. With respect to the waiting list, at the end of
2002, the 19 registrants aged 1–5 years represent contin-
ued growth, while the 37 recipients in the 6–10 year age
range was down to levels seen in 1998 after hitting a peak
of 49 in 2001. The reason for this decline is directly related
to the number of new registrants in this age group, which
has dropped drastically from a peak of 28 seen in 1999 to
only six in the last year. This decline in new registrants was
paralleled in children 11–17 years of age, where the num-
ber had fallen to 61, the second lowest for this age group
in the last 10 years. In fact, the number of new registrants
in the entire pediatric age range has continued to notably
decline, such that the 90 new registrants in 2002 represent
the lowest number in the last 10 years (Figure 17). While
this may reflect better medical care for patients with cystic
fibrosis (CF), it is not clear whether this is the entire expla-
nation. It is also unlikely that this decline is in any way
related to the advent of living donor lobar lung transplanta-
tion, because the majority of the recipients of this type of
transplant are also listed for a cadaveric organ. Finally, this
decline does not reflect a decrease in listing patients with
previous lung or heart-lung transplants, because these pa-
tients have never comprised more than 2–3% of patients
on the waiting list, reflecting a continued general unwilling-
ness for practitioners to proceed with retransplantation for
bronchiolitis obliterans.
Analyses of median waiting times to lung transplantation
in the pediatric age groups cannot be performed because
of the high death rates and long waiting times character-
istic of this age group. Examining instead the time until
25% of listed patients are transplanted, new registrants
younger than 1 year have a substantially shorter waiting
time than other pediatric and adult age groups. This may
be related to the very small number of new registrants
and thus a low level of competition for organs in this age
group. There is growing interest in directing pediatric de-
ceased lung donors to pediatric recipients, a policy already
established by the OPTN for heart transplant donors.
Waiting list mortality for the overall lung transplant candi-
date group has gradually declined over the last 10 years.
The rate of 131 per 1000 patient years at risk in 2002 is
close to one-half of the 1993 rate. This may reflect more
appropriate timing of listing of registrants for transplant
and better medical care. It does not reflect shorter wait-
ing times, because the time to transplant has generally
increased.
Within the pediatric population, registrants under 18 years
of age had a notably higher death rate while on the waiting
list than did their adult counterparts. In comparison with
the aforementioned rate of 131 per 1000 patient years at
risk for the overall lung transplant registrant population, the
rate in patients 1–5 years of age was 238 per 1000 patient
years at risk, the rate in patients 6–10 years of age was
210 per 1000 patient years at risk, and that in the teenage
group (10–17 years of age) was 148 per 1000 patient years
at risk. These data reflect the severity of illness for which
these candidates are being listed for lung transplantation,
as well as the scarcity of suitable donor organs. Exam-
ples of some of the entities for which these younger pa-
tients are being listed include forms of pulmonary alveolar
proteinosis (such as surfactant protein B deficiency), pul-
monary veno-occlusive disease, infantile interstitial pneu-
monitis, and idiopathic or secondary pulmonary hyperten-
sion. These entities can be very difficult to palliate, and use
of an extra-corporeal membrane oxygenator as a bridge
to transplant is rare, given the technical limitations as-
sociated with extracorporeal support in small pediatric
patients.
Transplantation and survival
In 2002, a total of 44 pediatric lung transplants (39 de-
ceased and five living donors) were performed. Over the
last 10 years, pediatric lung transplants have accounted for
3–6% of all recipients. Other than the group labeled con-
genital disease (CF not included), the relative distribution
of the primary disease entities leading to transplantation
has also remained stable over the 10-year period. The con-
genital disease group accounted for 6% of lung transplants
in 1993 and in 2002 accounted for less than 1%. The num-
bers of transplants performed have stayed relatively stable
in each pediatric age group over the last 5 years. The ma-
jority (64%) of pediatric recipients were in the 11–17 year
old age group, with CF being the most common disease in
these adolescent lung transplant recipients. CF was also
the primary diagnosis in the majority of living donor lung
transplants.
The number of living donor lung transplants performed in
the pediatric population peaked at 14 in 1998. The five
transplants performed in 2002 represent the lowest activ-
ity since 1996. In contrast with deceased donor lung trans-
plant recipients, in whom the primary diagnosis of retrans-
plant/graft failure has perennially accounted for 2–3% of all
transplants, in the living donor lung transplant population,
retransplantation/graft failure has accounted for 8–16% of
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Source: 2003 OPTN/SRTR Annual Report,Table 12.9a and 12.11a.  
Figure 18: Unadjusted 5-year graft and patient survival of de-
ceased donor lung transplants by recipient age, 2002.
transplants. This observation may suggest a practice to of-
fer retransplantation only in cases where a living donor can
be identified.
The incidence of lung transplantation in all pediatric age
groups was less than one per million population, well below
the incidence of heart transplantation in children. This fig-
ure is also substantially below the incidence of lung trans-
plantation observed in adults.
A history of prior organ transplant of any kind and the
need for life support at the time of transplant continue
to be associated with approximately double the annual
death rate per patient year at risk for recipients in the
first year after lung transplant. Because of the relatively
small numbers of pediatric lung transplants, analysis of
patient and graft survival is difficult. As demonstrated in
Figure 18, however, the available data suggest that 5-year
graft and patient survival is generally similar between pedi-
atric and adult recipients. Outcomes following living donor
lung transplantation are similar to those observed with
deceased donor transplantation. This lends further cred-
ibility to the importance of living donor lung transplanta-
tion as an acceptable mode of expanding the donor organ
pool.
Overall, the number of pediatric lung transplant recipients
and their survival has remained relatively stable, while the
number of new registrants and candidates on the wait-
ing list has declined. The survival benefit due to trans-
plantation in infancy (aged under 1 year) suggested by
the pediatric cardiac transplant data does not seem to be
borne out in the infant lung transplant survival data. The
development of novel forms of immunosuppression and
other therapies that obviate the development of bronchi-
olitis obliterans are concepts that remain at the forefront
for future improvement in outcomes. While living donor
lung transplantation has been established as a viable mode
of expanding the donor pool, other options must be ex-
plored. It remains to be seen whether ABO mismatched
transplantation, which has been introduced in infant car-




Pediatric registrants have accounted for 16–18% of all
heart-lung waiting list patients for the past 4 years. This
percentage is slightly larger than that seen in either the pe-
diatric heart or pediatric lung transplant populations. After
hitting a peak of 51 in 1998, the absolute number of pedi-
atric registrants awaiting heart-lung transplant has steadily
declined to 31 seen at year-end in 2002. The number of
new heart-lung transplant registrants reached its lowest
level in 10 years; the number of new registrants in 2002
(88) is approaching almost half of what it was in 1993 (162).
At 19, the number of new registrants in the pediatric age
range is the lowest recorded in the last 10 years. This find-
ing is probably multifactorial and includes the widespread
acceptance of lung transplantation and not heart-lung trans-
plantation as the procedure of choice for CF. Furthermore,
in patients with pulmonary hypertension associated with a
correctable congenital heart defect, transplant centers are
tending to opt for combining lung transplantation with an
intracardiac repair, unless there is a single ventricle cardiac
defect or the left ventricular function is prohibitively dimin-
ished. The majority of pediatric registrants are in the 11–17
year age group.
There continue to be insufficient data for the entire heart-
lung transplant waiting list population to determine median
waiting time to transplant. The overall waiting list death
rate among all heart-lung transplant candidates was 186
per 1000 patient years at risk. Children in the 1–5 year and
11–17 year age groups had rates notably higher at 333 and
326 per 1000 patient years at risk, respectively. These re-
sults may be related to a lack of circulatory support devices
to assist as a bridge to transplantation in the pediatric pop-
ulation. Likewise, the competition for organs between the
adult, adolescent, and pediatric populations may also factor
into these results.
Transplantation and survival
Over the last 10 years, pediatric candidates accounted for
8–23% of all heart-lung transplant recipients; of the 32
heart-lung transplants performed in 2002, 5 (16%) were
pediatric. Congenital disease and primary pulmonary hy-
pertension continue to be the most common diagnoses
treated with heart-lung transplant. As has been the case
throughout the last 10 years, the infrequency of heart-lung
transplantation in the pediatric population precludes calcu-
lation of annual death rates following transplantation.
Five-year graft and patient survival are difficult to analyze
in the pediatric patient heart-lung transplant population be-
cause the number of recipients is so low. For example,
while 5-year patient survival in the 11–17 year age group
is 50% and well above that of the overall heart-lung recip-
ient population (37%), the standard error is so large as to
make this relatively meaningless. It is generally accepted
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that survival rates for heart-lung transplantation in the pe-
diatric age range are similar to or slightly less than those
obtained in pediatric lung transplant recipients. As long
as heart-lung transplantation continues to be an unusual
form of therapy, it will be difficult to meaningfully analyze
its outcomes. As with all other forms of thoracic organ
transplantation, availability of donor organs (heart-lung
blocks) remains a limiting factor.
Reviewing all forms of thoracic transplantation in the pe-
diatric population, we can say that while the number of
new pediatric heart transplant registrants has reached its
highest level in the last 5 years, the number of new pe-
diatric lung and heart-lung registrants is declining. Waiting
list mortality for pediatric heart, lung, and heart-lung reg-
istrants is higher than that seen among adult registrants.
Increased severity of illness is one reason. The existence
of few options for cardiac support in this population of can-
didates is another. Needless to say, an ongoing shortage
of donor organs only serves to exacerbate this situation.
While living donor lung transplantation, ABO mismatched
infant cardiac transplant, and nonheartbeating donors have
been established as viable methods of expanding the donor
pool, other options must be explored.
Immunosupression
An accompanying article of this report, ‘Immunosuppres-
sion practice and trends’, provides an in-depth examina-
tion of practices across all types of organ transplants for
recipients of all ages over the last 10 years (46). A simi-
lar detailed analysis, restricted to pediatric patients, is be-
yond the scope of this article. Nonetheless, an age-specific
analysis of practices is worthy of study. There is growing
evidence that the pharmacokinetics of many immunosup-
pressive agents are substantively different between adults
and children (47–50). There are also different concerns re-
Table 1: Pediatric immunosuppression use (%) by organ
Organ
Kidney Liver Intestine Heart Lung
Induction drugs 67.9 20.3 46.3 43.7 55.0
ATGAM® 0.3 3.2 1.5 9.7 15.0
OKT3® 0.9 0.4 3.0 3.6 0.0
Thymoglobulin® 18.8 3.6 20.9 18.6 10.0
Zenapax® 23.2 8.3 9.0 7.5 30.0
Simulect® 26.8 4.9 11.9 6.1 0.0
Maintenance discharge/maintenance at end of first year
Calcineurin inhibitor use 93.4/90.8 97.9/97.0 98.2/100.0 98.8/93.9 94.7/91.7
Cyclosporine 22.5/30.8 11.3/9.4 0.0/0.0 60.9/48.9 57.9/16.7
Tacrolimus 71.4/60.6 88.3/88.6 98.2/100.0 43.0/45.5 42.1/75.0
Antimetabolite use 76.5/72.2 32.6/23.0 14.5/2.9 84.1/77.1 94.7/75.0
Azathioprine 5.0/9.5 3.8/2.1 0.0/0.0 35.7/22.9 63.2/33.3
Mycophenolate mofetil 72.6/63.1 28.8/20.8 14.5/2.9 58.9/54.1 36.8/41.7
Rapamycin use 18.2/13.9 3.4/4.9 18.2/8.6 1.9/3.5 5.3/0.0
Induction drugs and maintenance at discharge are for patients who received transplants in 2002; maintenance at 1 year following
transplant is for patients who received transplants in 2001. Source: OPTN/SRTR data as of August 2003.
garding the specific side-effects and toxicities of individ-
ual agents that are age dependent, including cosmesis,
growth, and development. Furthermore, as new immuno-
suppressive agents are introduced, there are frequently
different rates of integration into organ specific immuno-
suppressive strategies. It is likely that such practice differ-
ences exist between pediatric and adult programs as well.
The current use of immunosuppression by organ in pedi-
atric recipients is summarized in Table 1. The reported use
of induction therapy has declined over the last few years,
and the choice of agent has changed with the introduc-
tion of new agents. Induction use is still most common in
kidney transplantation. Half of all renal recipients received
an interleukin-2 receptor antagonist at time of transplant.
With respect to calcineurin inhibitors, tacrolimus is used
significantly more frequently than cyclosporin in kidney,
liver, and intestine transplantation, whereas cyclosporin
is used more frequently in heart and lung recipients. Ra-
pamycin was used as maintenance therapy in nearly a fifth
of all kidney transplants performed in 2002.
Comparison of the findings in Table 1 with data in the im-
munosuppression article in this report (46) reveals that in-
deed there are differences in practices between adults
and children, and these differences are frequently organ
specific. For example, in kidney transplantation, rapamycin
was used in 18% of pediatric recipients at the time of
transplant discharge compared with 15% of all renal re-
cipients. It is not possible to determine the exact reason
for this observation given the current data, but the greater
use of rapamycin observed in children may reflect an at-
tempt to introduce steroid-free protocols in the hope of
avoiding steroid-associated effects on growth. The rela-
tionship between age and rapamycin use is reversed with
respect to liver transplantation. Specifically, rapamycin was
used in 3% of pediatric liver recipients at the time of
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transplant discharge; overall use of rapamycin in liver re-
cipients of all ages was 7%. In heart transplantation the
difference was even more striking: only 2% of pediatric
heart recipients were discharged on rapamycin, whereas
the figure for heart transplant recipients of all ages is 10%.
With respect to calcineurin inhibitors, tacrolimus use in re-
nal recipients at discharge post-transplant is more com-
mon in pediatric recipients (71%) compared with kidney
recipients of all ages (63%). Again, specific reasons for this
difference cannot be determined, although it is possible
there is greater concern for cyclosporine-associated cos-
metic effects in the pediatric population. Tacrolimus use at
the time of transplant discharge is more common in pedi-
atric liver recipients (88%) compared with pediatric kidney
recipients, and the use is similar to liver recipients of all
ages (87%).
Another age-specific practice is apparent when exam-
ining the use of induction therapy in renal transplanta-
tion. With respect to polyclonal T-cell depleting agents,
equine antithymocyte globulin ATGAM® (Pharmacia & Up-
john Co., Kalamazoo, MI) and rabbit antithymocyte globu-
lin Thymoglobulin® (SangStat Medical Corp., Fremont, CA)
were both used less in pediatric renal recipients compared
with recipients of all ages (0.3% vs. 2% for ATG® and 19%
vs. 26% for Thymoglobulin®). These practices may reflect
concern over complications associated with aggressive in-
duction therapy, for example post-transplant lymphoprolif-
erative disorder, which is more common in the pediatric
population. Compared with transplant-specific recipients
of all ages, the use of interleukin-2 receptor antagonists
appears more common in pediatric kidney recipients, less
common in pediatric heart recipients, and approximately
equivalent in pediatric liver recipients.
These limited observations highlight differences in prac-
tices that are age specific. Consideration of these dif-
ferences is important when examining improvements in
patient and graft survival across age groups, as well as
immunosuppressive-associated morbidity.
Conclusion
This analysis of the OPTN/SRTR database serves to docu-
ment continued improvement with respect to graft and pa-
tient survival over the decade for those pediatric patients
with end-stage organ disease who are fortunate enough
to receive a transplant. While these advances have been
observed for liver, intestine, and thoracic transplantation,
these improvements have been best characterized in the
renal transplant population. One-year graft survival for both
living and deceased donor renal transplants is excellent
across all pediatric age groups and now equals or exceeds
the survival rates seen in adult recipients. Long-term graft
survival is also excellent, except for adolescent recipients
who have survival rates well below those of all but the
very oldest adult recipients. The reasons for this striking
discrepancy within the pediatric population are not known.
While there may be organ-specific factors responsible,
many believe that issues related to compliance to the im-
munosuppressive regimen play a pivotal role in these ado-
lescent recipients. Ongoing efforts to determine the poten-
tial role of noncompliance and to design interventions to
improve outcomes should be encouraged. If compliance is
indeed a causative factor, it is reasonable to postulate that
this problem is age-specific rather than organ-specific, and
progress made in this area could translate into improved
outcomes for all adolescent transplant recipients.
While the significant improvements in graft and patient sur-
vival are laudable, waiting list mortality remains a signif-
icant issue. Pediatric candidates awaiting liver, intestine,
and thoracic transplantation face mortality rates that are
generally greater than their adult counterparts, and this
effect is particularly pronounced in patients aged 5 years
and younger. In certain subgroups, such as children aged
under 1 year awaiting liver, intestine, and heart transplan-
tation, this risk can be five- to sixfold higher than other
patients awaiting transplantation. Strategies aimed at re-
ducing waiting list mortality are vital. While improvements
in care of children with end-stage organ disease can make
an impact, improving access to transplantation is critical.
To better address issues related to waiting list mortality,
the transplantation community has attempted to develop
fair allocation strategies that focus on medical urgency
rather than waiting time. Some of these strategies, such
as MELD/PELD, use predicted mortality as the measure
of medical urgency. While mortality may be a reasonable
starting point for adult patients, it is important to realize
that other issues in addition to mortality are critical for chil-
dren. Consideration of the effect of end-stage organ dis-
ease on growth and development is often equally impor-
tant, both while awaiting transplant and after transplanta-
tion. Development of an evidence-based, quantitative ap-
proach to measuring the relative role of these other factors
could prove crucial. It is to be hoped that continued refine-
ments in allocation policy will continue to emphasize the
importance of directing organs to those recipients most in
need of transplantation and most likely to benefit from this
therapy.
Within the pediatric population, several strategies may help
to improve access to transplantation. In some cases, such
as for patients awaiting liver and intestine transplantation,
the initial allocation system underestimated the mortality
risk faced by these patients. Based on ongoing data anal-
ysis, the allocation system has been adjusted accordingly.
More donor organs are another obvious solution, although
finding an appropriate donor can be challenging in small
children. In kidney transplantation, graft size is not an issue,
and the same is true to a lesser extent in liver transplanta-
tion. In the case of intestinal and thoracic organ transplan-
tation, issues related to graft size directly affect the pool
of potential donor organs. It is vital that no pediatric donor
goes underutilized.
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Pediatric patients accounted for 3% of all patients awaiting
transplantation at the end of 2002 and 7% of all transplants
performed. While, at first glance, these figures may seem
unbalanced with respect to listing and transplantation, it is
noteworthy that the representation of pediatric deceased
organ donors is more than twofold higher compared with
recipients of such organs. In 2002, individuals under 18
years of age accounted for 15% of all deceased donors.
This observation should discredit any belief that pediatric
patients are receiving a disproportionate share of this life-
saving resource.
Significant progress has been made in the care of pediatric
transplant patients. Changes in supportive therapy prior
to transplant, donor selection, operative management, im-
munosuppressive therapy, and long-term follow up have
all affected the care of these children. Some of these ad-
vances reflect lessons learned from across the pediatric
population, whereas other advances reflect information
gathered across all ages in organ-specific areas. It is vital
to critically evaluate and integrate new information from all
sources, while being mindful of the knowledge that these
young patients represent a unique group, with issues dis-
tinct from their adult counterparts.
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